世界の腎臓がん治療・診断市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Kidney Cancer Therapeutics and Diagnostics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12415 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、腎臓がん治療・診断のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。腎臓がん治療・診断の種類別市場規模（膀胱鏡検査、生検、静脈内腎盂造影、CTスキャン、腎臓超音波、その他）、用途別市場規模（病院、製薬研究所、ゲノミクス研究所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・腎臓がん治療・診断の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bayer、Hoffmann La Roche、GlaxoSmithKline、Novartis、Pfizer、Abbott Laboratories、Amgen、Genentech、Cerulean Pharma、Seattle Genetics ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：膀胱鏡検査、生検、静脈内腎盂造影、CTスキャン、腎臓超音波、その他 ・用途別分析2016年-2026年：病院、製薬研究所、ゲノミクス研究所、その他 ・腎臓がん治療・診断の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・腎臓がん治療・診断のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・腎臓がん治療・診断のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・腎臓がん治療・診断の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・腎臓がん治療・診断の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Kidney Cancer Therapeutics and Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Kidney Cancer Therapeutics and Diagnostics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Kidney Cancer Therapeutics and Diagnostics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Kidney Cancer Therapeutics and Diagnostics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Cystoscopy
Biopsy
Intravenous Pyelogram
CT Scan
Kidney Ultrasound
Others

Market segment by Application, can be divided into
Hospitals
Pharmaceutical Labs
Genomics Laboratories
Others

Market segment by players, this report covers
Bayer
Hoffmann La Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Amgen
Genentech
Cerulean Pharma
Seattle Genetics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Kidney Cancer Therapeutics and Diagnostics
1.2 Classification of Kidney Cancer Therapeutics and Diagnostics by Type
1.2.1 Overview: Global Kidney Cancer Therapeutics and Diagnostics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Type in 2020
1.2.3 Cystoscopy
1.2.4 Biopsy
1.2.5 Intravenous Pyelogram
1.2.6 CT Scan
1.2.7 Kidney Ultrasound
1.2.8 Others
1.3 Global Kidney Cancer Therapeutics and Diagnostics Market by Application
1.3.1 Overview: Global Kidney Cancer Therapeutics and Diagnostics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Pharmaceutical Labs
1.3.4 Genomics Laboratories
1.3.5 Others
1.4 Global Kidney Cancer Therapeutics and Diagnostics Market Size & Forecast
1.5 Global Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast by Region
1.5.1 Global Kidney Cancer Therapeutics and Diagnostics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Kidney Cancer Therapeutics and Diagnostics Market Size by Region, (2016-2021)
1.5.3 North America Kidney Cancer Therapeutics and Diagnostics Market Size and Prospect (2016-2026)
1.5.4 Europe Kidney Cancer Therapeutics and Diagnostics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Market Size and Prospect (2016-2026)
1.5.6 South America Kidney Cancer Therapeutics and Diagnostics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Kidney Cancer Therapeutics and Diagnostics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Kidney Cancer Therapeutics and Diagnostics Market Drivers
1.6.2 Kidney Cancer Therapeutics and Diagnostics Market Restraints
1.6.3 Kidney Cancer Therapeutics and Diagnostics Trends Analysis
2 Company Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.1.4 Bayer Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Hoffmann La Roche
2.2.1 Hoffmann La Roche Details
2.2.2 Hoffmann La Roche Major Business
2.2.3 Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.2.4 Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Hoffmann La Roche Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.3.4 GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.4.4 Novartis Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.5.4 Pfizer Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Abbott Laboratories
2.6.1 Abbott Laboratories Details
2.6.2 Abbott Laboratories Major Business
2.6.3 Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.6.4 Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Abbott Laboratories Recent Developments and Future Plans
2.7 Amgen
2.7.1 Amgen Details
2.7.2 Amgen Major Business
2.7.3 Amgen Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.7.4 Amgen Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Amgen Recent Developments and Future Plans
2.8 Genentech
2.8.1 Genentech Details
2.8.2 Genentech Major Business
2.8.3 Genentech Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.8.4 Genentech Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Genentech Recent Developments and Future Plans
2.9 Cerulean Pharma
2.9.1 Cerulean Pharma Details
2.9.2 Cerulean Pharma Major Business
2.9.3 Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.9.4 Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Cerulean Pharma Recent Developments and Future Plans
2.10 Seattle Genetics
2.10.1 Seattle Genetics Details
2.10.2 Seattle Genetics Major Business
2.10.3 Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Product and Solutions
2.10.4 Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Seattle Genetics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Kidney Cancer Therapeutics and Diagnostics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Kidney Cancer Therapeutics and Diagnostics Players Market Share
3.2.2 Top 10 Kidney Cancer Therapeutics and Diagnostics Players Market Share
3.2.3 Market Competition Trend
3.3 Kidney Cancer Therapeutics and Diagnostics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Kidney Cancer Therapeutics and Diagnostics Revenue and Market Share by Type (2016-2021)
4.2 Global Kidney Cancer Therapeutics and Diagnostics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Application (2016-2021)
5.2 Kidney Cancer Therapeutics and Diagnostics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2026)
6.2 North America Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2026)
6.3 North America Kidney Cancer Therapeutics and Diagnostics Market Size by Country
6.3.1 North America Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2026)
6.3.2 United States Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
6.3.3 Canada Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
6.3.4 Mexico Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2026)
7.2 Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2026)
7.3 Europe Kidney Cancer Therapeutics and Diagnostics Market Size by Country
7.3.1 Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2026)
7.3.2 Germany Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
7.3.3 France Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
7.3.5 Russia Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
7.3.6 Italy Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2026)
8.2 Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2026)
8.3 Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Market Size by Region
8.3.1 Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Region (2016-2026)
8.3.2 China Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
8.3.3 Japan Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
8.3.4 South Korea Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
8.3.5 India Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
8.3.7 Australia Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2026)
9.2 South America Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2026)
9.3 South America Kidney Cancer Therapeutics and Diagnostics Market Size by Country
9.3.1 South America Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2026)
9.3.2 Brazil Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
9.3.3 Argentina Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2026)
10.2 Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2026)
10.3 Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Market Size by Country
10.3.1 Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2026)
10.3.2 Turkey Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
10.3.4 UAE Kidney Cancer Therapeutics and Diagnostics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Kidney Cancer Therapeutics and Diagnostics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Kidney Cancer Therapeutics and Diagnostics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Kidney Cancer Therapeutics and Diagnostics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Region (2021-2026)
Table 6. Bayer Corporate Information, Head Office, and Major Competitors
Table 7. Bayer Major Business
Table 8. Bayer Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 9. Bayer Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Hoffmann La Roche Corporate Information, Head Office, and Major Competitors
Table 11. Hoffmann La Roche Major Business
Table 12. Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 13. Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 15. GlaxoSmithKline Major Business
Table 16. GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 17. GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 21. Novartis Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Pfizer Corporate Information, Head Office, and Major Competitors
Table 23. Pfizer Major Business
Table 24. Pfizer Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 25. Pfizer Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 27. Abbott Laboratories Major Business
Table 28. Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 29. Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Amgen Corporate Information, Head Office, and Major Competitors
Table 31. Amgen Major Business
Table 32. Amgen Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 33. Amgen Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Genentech Corporate Information, Head Office, and Major Competitors
Table 35. Genentech Major Business
Table 36. Genentech Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 37. Genentech Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Cerulean Pharma Corporate Information, Head Office, and Major Competitors
Table 39. Cerulean Pharma Major Business
Table 40. Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 41. Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Seattle Genetics Corporate Information, Head Office, and Major Competitors
Table 43. Seattle Genetics Major Business
Table 44. Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Product and Solutions
Table 45. Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) by Players (2019-2021)
Table 47. Global Kidney Cancer Therapeutics and Diagnostics Revenue Share by Players (2019-2021)
Table 48. Breakdown of Kidney Cancer Therapeutics and Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Kidney Cancer Therapeutics and Diagnostics Players Head Office, Products and Services Provided
Table 50. Kidney Cancer Therapeutics and Diagnostics Mergers & Acquisitions in the Past Five Years
Table 51. Kidney Cancer Therapeutics and Diagnostics New Entrants and Expansion Plans
Table 52. Global Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) by Type (2016-2021)
Table 53. Global Kidney Cancer Therapeutics and Diagnostics Revenue Share by Type (2016-2021)
Table 54. Global Kidney Cancer Therapeutics and Diagnostics Revenue Forecast by Type (2021-2026)
Table 55. Global Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2021)
Table 56. Global Kidney Cancer Therapeutics and Diagnostics Revenue Forecast by Application (2021-2026)
Table 57. North America Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Kidney Cancer Therapeutics and Diagnostics Picture
Figure 2. Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Type in 2020
Figure 3. Cystoscopy
Figure 4. Biopsy
Figure 5. Intravenous Pyelogram
Figure 6. CT Scan
Figure 7. Kidney Ultrasound
Figure 8. Others
Figure 9. Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Application in 2020
Figure 10. Hospitals Picture
Figure 11. Pharmaceutical Labs Picture
Figure 12. Genomics Laboratories Picture
Figure 13. Others Picture
Figure 14. Global Kidney Cancer Therapeutics and Diagnostics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global Kidney Cancer Therapeutics and Diagnostics Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Region (2016-2026)
Figure 17. Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Region in 2020
Figure 18. North America Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Middle East and Africa Kidney Cancer Therapeutics and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Kidney Cancer Therapeutics and Diagnostics Market Drivers
Figure 24. Kidney Cancer Therapeutics and Diagnostics Market Restraints
Figure 25. Kidney Cancer Therapeutics and Diagnostics Market Trends
Figure 26. Bayer Recent Developments and Future Plans
Figure 27. Hoffmann La Roche Recent Developments and Future Plans
Figure 28. GlaxoSmithKline Recent Developments and Future Plans
Figure 29. Novartis Recent Developments and Future Plans
Figure 30. Pfizer Recent Developments and Future Plans
Figure 31. Abbott Laboratories Recent Developments and Future Plans
Figure 32. Amgen Recent Developments and Future Plans
Figure 33. Genentech Recent Developments and Future Plans
Figure 34. Cerulean Pharma Recent Developments and Future Plans
Figure 35. Seattle Genetics Recent Developments and Future Plans
Figure 36. Global Kidney Cancer Therapeutics and Diagnostics Revenue Share by Players in 2020
Figure 37. Kidney Cancer Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 38. Global Top 3 Players Kidney Cancer Therapeutics and Diagnostics Revenue Market Share in 2020
Figure 39. Global Top 10 Players Kidney Cancer Therapeutics and Diagnostics Revenue Market Share in 2020
Figure 40. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 41. Global Kidney Cancer Therapeutics and Diagnostics Revenue Share by Type in 2020
Figure 42. Global Kidney Cancer Therapeutics and Diagnostics Market Share Forecast by Type (2021-2026)
Figure 43. Global Kidney Cancer Therapeutics and Diagnostics Revenue Share by Application in 2020
Figure 44. Global Kidney Cancer Therapeutics and Diagnostics Market Share Forecast by Application (2021-2026)
Figure 45. North America Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Type (2016-2026)
Figure 46. North America Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Application (2016-2026)
Figure 47. North America Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 48. United States Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Canada Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Mexico Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Europe Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Type (2016-2026)
Figure 52. Europe Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Application (2016-2026)
Figure 53. Europe Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 54. Germany Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. France Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. United Kingdom Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Russia Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Italy Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Type (2016-2026)
Figure 60. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Application (2016-2026)
Figure 61. Asia-Pacific Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Region (2016-2026)
Figure 62. China Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Japan Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South Korea Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. India Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Southeast Asia Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Australia Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South America Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Type (2016-2026)
Figure 69. South America Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Application (2016-2026)
Figure 70. South America Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 71. Brazil Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Argentina Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Middle East and Africa Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Type (2016-2026)
Figure 74. Middle East and Africa Kidney Cancer Therapeutics and Diagnostics Sales Market Share by Application (2016-2026)
Figure 75. Middle East and Africa Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. UAE Kidney Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Methodology
Figure 80. Research Process and Data Source

---